Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis gets FDA OK for new Famvir indications
The FDA also approved Famvir (famciclovir) as a single-dose treatment for recurrent herpes labialis (cold sores) in immunocompetent patients. When an outbreak of recurrent genital herpes (RGH) is
The FDA also approved Famvir (famciclovir) as a single-dose treatment for recurrent herpes labialis (cold sores) in immunocompetent patients. When an outbreak of recurrent genital herpes (RGH) is
Napo Pharmaceuticals is focused on developing and commercializing proprietary pharmaceuticals, in collaboration with local partners, to address major global unmet medical needs in developed and developing countries. The
The researchers used the approach to successfully reverse symptoms in mice with a form of muscular dystrophy that damages the heart. They also tested the virus-based delivery method
Vaso has shipped the products to Pathmark Stores, which operates a 140-store supermarket chain in New Jersey, New York, Pennsylvania and Delaware. Vaso’s PENtoCORE technology is a topical
Seredigm was founded to commercialize proprietary compositions that protect against tissue damage in a variety of acute or chronic medical conditions. Tissue damage plays a critical role in
Xolegel (ketoconazole, USP), previously referred to as Sebazole, is a topical formulation of 2% ketoconazole, an antifungal agent, in a waterless gel for once-daily application. Xolegel is the
The anthrax immune globulin (AIG) is to be made available for treating or preventing inhalational anthrax. The value of the deal, which comes as a modification to the
The secretion of the cytokine TNF-alpha underlies a range of debilitating inflammatory diseases such as rheumatoid arthritis, lupus, Crohn’s disease, psoriasis, and ankylosing spondylitis, and is considered to
For the three months to June 30, 2006 product sales increased by 7% to $376 million, compared to $351.6 million in Q2 2005. This was driven by Adderall
The European Commission’s conditional authorization of Sutent (sunitinib malate) to treat advanced and/or metastatic renal cell carcinoma (mRCC) after failure of interferon alfa and interleukin-2 therapies is based